Zikani Therapeutics Inc.
www.zikani.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zikani Therapeutics Inc.
Agios Anticipates PK Deficiency Diagnosis Ramp-Up After Pyrukynd Approval
The company hopes to grow the current diagnostic rate from 30% to 70% over two to five years. “Optimal reimbursement” for mitapivat will likely take a year, with Medicare/Medicaid lagging.
PerkinElmer To Buy UK-Based Immunodiagnostics For $155M
PerkinElmer will add chemiluminescence products in endocrinology, autoimmunity and diagnostics to its portfolio with the planned buyout of Immunodiagnostics.
Deal Watch: Artios Links Up With Novartis On DNA Damage Response Modifiers
Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.
Venture Funding Deals: Four $100m-Plus Rounds, Including Allogene's $300m
April had four VC rounds of $100m or more, including Allogene's $300m to develop CAR-T therapies licensed from Pfizer. Innovent Biologics raised $150m, BenevolentAI brought in $115m and Constellation garnered $100m last month.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Eloxx Pharmaceuticals, Inc.
- Macrolide Pharmaceuticals Inc.